Vor Biopharma Inc

NASDAQ VOR

Data sourced from

and

Download Data

Vor Biopharma Inc Non-current Liabilities to Total Liabilities Ratio for the quarter ending March 31, 2024: 0.70

Vor Biopharma Inc Non-current Liabilities to Total Liabilities Ratio is 0.70 for the quarter ending March 31, 2024, a -4.70% change year over year. The total non-current liabilities to total liabilities ratio measures the proportion of a company's non-current liabilities to its total liabilities. It is calculated by dividing the total non-current liabilities by the total liabilities. This ratio provides insights into the composition of a company's liabilities and the extent to which it relies on long-term debt and obligations. A higher ratio indicates a greater reliance on non-current liabilities, suggesting potential long-term financial commitments and increased financial risk.

Vor Biopharma Inc Non-current Liabilities to Total Liabilities Ratio for the quarter ending March 31, 2023 was 0.73, a 34.87% change year over year.
Vor Biopharma Inc Non-current Liabilities to Total Liabilities Ratio for the quarter ending March 31, 2022 was 0.54, a -18.12% change year over year.
Vor Biopharma Inc Non-current Liabilities to Total Liabilities Ratio for the quarter ending March 31, 2021 was 0.66.

NASDAQ: VOR

Vor Biopharma Inc

CEO	Dr. Robert Ang M.B.A., M.D., MBBS
IPO Date	Feb. 5, 2021
Location	United States
Headquarters	100 Cambridgepark Drive, Cambridge, MA, United States, 02140
Employees	168
Sector	Healthcare
Industry	Biotechnology

Description

Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Key trends